6ZB.F LINC AB
- Market cap
- EUR 363M
- P/E
- 57.4x
- P/B
- 0.87x
- ROE
- 5.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6ZB.F undervalued?
Graham number6ZB.F trades 49.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LINC AB fundamental analysis
No fundamental analysis for LINC AB yet.
LINC AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LINC AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies. It usually…
Full company profileLINC AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LINC AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.37M | 3.65M | 0.00 | 5.00M | 2.31M |
| Gross Profit | -2.66M | -1.89M | -7.88M | -1.59M | -8.33M |
| Operating Income | -898M | 649M | 1.28B | -423M | 244M |
| EBITDA | -896M | 666M | 1.30B | -407M | 254M |
| Net Income | -723M | 619M | 1.30B | -400M | 241M |
| EPS | -12 | 11 | 22 | -6.90 | 4.18 |
| Balance Sheet | |||||
| Total Assets | 2.91B | 3.53B | 4.84B | 4.44B | 4.59B |
| Total Liabilities | 2.85M | 2.92M | 8.76M | 11.6M | 3.52M |
| Shareholders' Equity | 2.91B | 3.53B | 4.83B | 4.43B | 4.59B |
| Cash & Short-term Investments | 601M | 520M | 550M | 284M | 65.6M |
| Cash Flow | |||||
| Operating Cash Flow | -228M | -80.6M | 29.7M | -266M | -261M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -228M | -80.6M | 29.7M | -266M | -261M |
| Ratios | |||||
| ROE | -24.9% | 17.6% | 26.9% | -9.0% | 5.3% |
| ROA | -24.8% | 17.5% | 26.9% | -9.0% | 5.2% |
| Net Profit Margin | -30,507.6% | 16,971.5% | - | -7,992.9% | 10,415.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LINC AB dividends
LINC AB has not paid dividends in the last 4 fiscal years.
Who owns LINC AB
- Insiders 60.77%
- Institutions 25.24%
- Public & others 13.99%
- Shares outstanding 57.5M
- Free float 22.7M
LINC AB company profile
- Company name
- LINC AB
- Ticker
- 6ZB.F
- ISIN
- SE0015949433
- Exchange
- Frankfurt Exchange
- Sector
- Financial Services
- Industry
- Capital Markets
- Employees
- 2
- Fiscal year end
- December
- Address
- Vasagatan 28, Stockholm, Sweden, 111 20
- Phone
- 46 709 35 85 74
- Website
- linc.se/?lang=en
About LINC AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million ($2.99 million) and SEK 250 million ($29.99 million), the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB was founded in 1991 and based in Stockholm, Sweden.
LINC AB management
2- Mr. Karl TobiesonChief Executive Officer · born 1974
- Mr. Thomas BerghChief Financial Officer · born 1982